Psilocybin reduces symptoms of major depression: The Lancet

Published Date: 04 Mar 2023

A new study by Robin von Rotz and his team found that moderate doses of psilocybin for at least two weeks reduced symptoms of depression...

Read Full News

Latest News

Increases in Physician Attrition Rates Could Worsen Shortages

Increases in Physician Attrition Rates Could Worsen Shortages

Improving CRC Screening Rates With High-Quality, Noninvasive Tests, with Keith Winfrey, MD, MPH Keith Winfrey, MD, MPH

Winfrey discussed how noninvasive CRC screening tests can help meet gaps when patients face barriers to colonoscopy.

ACP Urges Concern for Health Policy Issues, with Shari Erickson, MPH Shari Erickson, MPH

Erickson discussed key health policy issues the ACP is pushing back against during the organization’s Internal Medicine meeting.

Reviving exhausted immune cells boosts tumor elimination

A new study has discovered a molecular signal that tumors exploit to exhaust the T cells meant to destroy them—and how silencing that signal could revive the body's immunity.

Precision therapy could stop breast cancer at the source

Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer (TNBC), which is among the most aggressive and difficult-to-treat forms of ...

What are the big unanswered questions about cancer? Experts discuss

Over the 40-year history of the University of Colorado Cancer Center, its investigators have answered many questions about cancer—what causes it, how to prevent it, and how to treat it. Those discoveries have helped many ...

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Latest News

Increases in Physician Attrition Rates Could Worsen Shortages

Winfrey discussed how noninvasive CRC screening tests can help meet gaps when patients face barriers to colonoscopy.

Erickson discussed key health policy issues the ACP is pushing back against during the organization’s Internal Medicine meeting.

A new study has discovered a molecular signal that tumors exploit to exhaust the T cells meant to destroy them—and how silencing that signal could revive the body's immunity.

Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer (TNBC), which is among the most aggressive and difficult-to-treat forms of ...

Over the 40-year history of the University of Colorado Cancer Center, its investigators have answered many questions about cancer—what causes it, how to prevent it, and how to treat it. Those discoveries have helped many ...

News All Time

Global reviews call for urgent action on endometriosis in most world regions

Two reviews published in The Lancet Obstetrics, Gynecology & Women's Health reveal stark global inequities in how endometriosis is recognized, treated, and prioritized in national health systems.

Mental and physical coaching before surgery prepares immune system and reduces complications, trial finds

The weeks leading up to a major surgery can be a time of uncertainty and worry for patients, many of whom anticipate the need for rehabilitation to get back on their feet. But if patients improve their physical and mental ...

Flu vaccine performance varies by age, study reveals

New research comparing four different flu vaccines found that the ability of the vaccines to activate cells of the immune system that help to protect against infection varied greatly depending on the vaccine type and age ...

Study reveals why some myeloma patients stay cancer-free for years after CAR T therapy

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell therapy, while others see ...

Researchers aim to disrupt breast cancer line of communication and prevent spread

Cancer Center at Illinois (CCIL) Program Leader Erik Nelson's lab made an important discovery about the relationship between cholesterol and breast cancer progression with crucial implications for breast cancer therapeutics.

Study tracking how tumor microenvironment develops signals opportunity for early detection, risk prediction

Colorectal cancer precursor lesions are benign growths that can develop into colorectal cancer (CRC) over time, through either a conventional or serrated pathway. Understanding how the immune system reacts to these precursor ...

Rapid growth of radiopharmaceutical therapy highlights need for expertise

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining the education, training, and experience needed to ensure the safe and effective delivery of radiopharmaceutical therapy ...

Newly identified lymphoma subtype gives hope in fight against aggressive form of blood cancer

Researchers at the University of Southampton have identified a new subtype of lymphoma that could pave the way to improved and more targeted treatments for some blood cancer patients. The cancer scientists and biologists ...

Blood test offers hope for more effective ovarian cancer treatment

New clinical research has identified a blood test that can reveal which women are more likely to respond to a particular treatment for ovarian cancer, known as PARP inhibitor therapy.

Q&A: Connection between a distinct immune cell and colitis discovered

CU Anschutz researchers uncovered a link between a type of mucosal immune cell and gut inflammation, finding that the cells exacerbate inflammation and lead to chronic disease in certain conditions.

FDA grants fast track designation to drug combo for colorectal cancer

The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer, following encouraging results from a clinical trial led in part by the University of Oklahoma ...

T cell therapies show long-term HPV gains

Researchers from Rutgers Cancer Institute, New Jersey's only National Cancer Institute (NCI)—designated Comprehensive Cancer Center, and RWJBarnabas Health, along with colleagues from the National Cancer Institute, a center ...

Sleep issues linked to higher risk of severe asthma in children

About 30 to 40% of children with asthma experience sleep difficulties due to symptoms like coughing and wheezing. Poor sleep increases the risk of severe asthma exacerbations (attacks) that often necessitate a hospitalization ...

Largest study on infant-type hemispheric glioma reports factors to guide treatment approaches

Clinician-scientists at St. Jude Children's Research Hospital and collaborators have conducted the largest study of infant-type hemispheric glioma (IHG) ever reported, uncovering key factors that could be used to guide treatment ...

What is myasthenia gravis, the rare disease tennis great Monica Seles lives with?

Former tennis star Monica Seles recently revealed she is living with the rare disease myasthenia gravis, which affects 12 in 100,000 people globally.

Factoring in frailty and age could improve pancreatic cancer treatment

While some risk factors for cancer can be mitigated through lifestyle choices such as diet or exercise, aging is not one of them. In the case of pancreatic cancer, it also can limit treatment options if a patient is too frail ...

Recommended News For You

NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?

Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA.

Legal, Recreational Marijuana Linked to Higher CUD Prevalence.

Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

Radiotherapy after mastectomy can be avoided, study finds

Preoperative Embolization Linked to Relapse-Free Survival in Meningioma

Recommended Articles For You

PARP Inhibitors in Testicular Cancer: Tackling Cisplatin Resistance with Precision 

The Importance of Having a Quick and Effective Heparin Antidote  

Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells 

The Lung Cancer Shift: From Reactive Treatment to Proactive Precision Medicine 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

As EGFR internalization is decreased, BUB1 controls EGFR signaling.

2.

A paper strip test might enable the early detection of cancer.

3.

Breast cancer patients' arms swell less after an effective lymph node transfer.

4.

A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll

5.

For fit patients with CLL, frontline venetoclax-ibrutinib improves survival.

1.

CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target

2.

Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment

3.

Seeing the Unseen: Examining Chancroid Through Images

4.

Beyond the Standard: Personalized Cancer Vaccines and the Dawn of a New Era in Pediatric Oncology

5.

Unveiling the Mystery of Epstein-Barr Virus: What We Know So Far

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Efficient Management of First line ALK-rearranged NSCLC

2.

Navigating the Complexities of Ph Negative ALL - Part IV

3.

Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

5.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot